Fortress Biotech Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

FBIO$1.91-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

($ in thousands)


· · Year Ended December 31,
· 2023 · 2022
Cash Flows from Operating Activities: · ·
Net loss	$(154,154)	$(213,913)
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense	2,230	3,109
(Gain) loss on sale of property and equipment	(1,466)	255
Bad debt expense	435	284
Amortization of debt discount	3,032	2,065
Accretion of partner company convertible preferred shares	757	—
Non-cash interest	353	770
Loss on extinguishment of debt	2,796	—
Amortization of acquired intangible assets	3,767	4,277
Reduction in the carrying amount of operating lease right-of-use assets	2,078	1,967
Stock-based compensation expense	17,029	22,987
Issuance of partner company’s common shares for research and development expenses	1,240	—
Common shares issued for dividend on partner company's convertible preferred shares	266	—
Change in fair value of partner companies' warrant liabilities	(4,424)	(1,129)
Research and development - licenses acquired, expense	3,085	642
Loss from deconsolidation/dissolution of subsidiaries	4,127	—
Asset impairment loss	3,143	—
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Accounts receivable	12,551	(5,380)
Inventory	3,953	1,744
Other receivables - related party	(29)	540
Prepaid expenses and other current assets	(848)	(2,595)
Other assets	(808)	344
Accounts payable and accrued expenses	(24,382)	8,349
Deferred revenue	—	(1,883)
Income taxes payable	121	377
Lease liabilities	(2,291)	(2,025)
Other long-term liabilities	(786)	(186)
Net cash used in operating activities	(128,225)	(179,401)

Cash Flows from Investing Activities:
Purchase of research and development licenses	(3,035)	(340)
Purchase of property and equipment	(63)	(2,715)
Proceeds from sale of property and equipment	6,000	127
Other	(5)	—
Acquisition of VYNE products	—	(20,000)
Acquired intangible assets	(5,000)	—
Net cash used in investing activities	(2,103)	(22,928)

Consolidated Statements of Cash Flows

($ in thousands)


· · Year Ended December 31,
· · 2023 · · 2022
Cash Flows from Financing Activities: · ·
Payment of Series A perpetual preferred stock dividends	$(8,032)	$(8,031)
Proceeds from issuance of common stock for public offering, net	22,078	—
Proceeds from issuance of common stock for at-the-market offering, net	2,041	6,053
Proceeds from issuance of common stock under ESPP	—	174
Exercise of warrants for cash	382	—
Proceeds from partner companies' ESPP	178	206
Partner company’s dividends declared and paid	(736)	(749)
Partner company’s redemption of preferred shares	(400)	(85)
Proceeds from partner companies' sale of stock and warrants, net	51,637	17,835
Proceeds from partner companies' at-the-market offering, net	4,620	16,370
Proceeds from exercise of partner companies’ options and warrants, net	121	290
Partner company’s net settlement of shares withheld for taxes	—	(1,698)
Partner company's cash payout for reverse stock split fractional shares	—	(6)
Payment of partner company's repurchase of stock	—	(1,105)
Payment of partner company's deferred financing cost	—	(119)
Repayment of partner company installment payments - licenses	(1,000)	(5,000)
Proceeds from partner company convertible preferred shares	854	2,533
Payment of debt issuance costs associated with partner company convertible preferred shares	(210)	(597)
Proceeds from partner companies' long-term debt, net	14,529	47,112
Repayment of partner companies' long-term debt	(50,375)	—
Proceeds from partner company's line of credit	28,000	5,000
Repayment of partner company's line of credit	(30,948)	(2,864)
Net cash (used in) provided by financing activities	32,739	75,319
Net decrease in cash and cash equivalents and restricted cash	(97,589)	(127,010)
Cash and cash equivalents and restricted cash at beginning of period	180,954	307,964
Cash and cash equivalents and restricted cash at end of period	$83,365	$180,954

Supplemental disclosure of cash flow information:
Cash paid for interest	$7,945	$9,419
Cash paid (refunded) for income taxes	$(55)	$858

Supplemental disclosure of non-cash financing and investing activities:
Conversion of partner company annual maintenance fee to a promissory note	$—	$268
Partner company's unpaid intangible assets	$—	$4,740
Unpaid partner company’s debt offering cost	$—	$1,058
Unpaid partner company’s offering cost	$263	$4
Partner company’s retained earning adjustment	$—	$195
Partner company’s reclassification of warrant liability to equity	$—	$89
Partner company derivative warrant liability associated with partner company convertible preferred shares	$33	$90
Partner company's warrants issued in conjunction with debt	$—	$384
Unpaid research and development licenses acquired	$50	$325
Lease Liabilities arising from obtaining right-of-use assets	$923	$2,953

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.